Marc Ullman weighed in on a story in NutraIngredients-USA.com entitled, “Amarin’s ITC case against omega-3s players decried as attempt to corner EPA market.”

The article discusses how, as the concentration levels of omega-3 dietary supplement products have steadily risen, pharmaceutical manufacturer Amarin has moved to protect its competitive turf by filing a trade complaint against

Marc Ullman was interviewed for an article entitled, “ChromaDex-Elysium fight highlights glitches in NDI and GRAS processes.” The article discusses the tussle between ChromaDex and Elysium Health, which highlights the curious dance between a New Dietary Ingredient Notification and a GRAS affirmation as a way to bring ingredients to market.

To read the article, click

Marc Ullman will participate on a panel for a workshop entitled, “FDA Lawsuits and Class Action Litigation in the Dietary Supplement Industry,” to be held at the SupplySide West annual conference.

The September 26 workshop, which will take place at the Mandalay Bay Expo Hall in Las Vegas, will examine the FDA’s years-long court battle

On October 5, Geoffrey Kaiser will participate in a Practising Law Institute (PLI) Enforcement Trends panel at the Institute’s Life Sciences conference. The program, entitled, “Life Sciences 2017: Navigating Legal Challenges in the Drug and Device Industries,” will be held in New York City.

For information and registration, click here.

Brian Bank has been appointed Chair of the Employment and Labor Litigation Committee of the American Bar Association’s Tort Trial and Insurance Practice Section.

Marc Ullman was quoted in Natural Products Insider’s article: “Hi-Tech Files Appeal in DMAA Fight with FDA,” which discusses Hi-Tech Pharmaceuticals Inc.’s quarrel with the federal government regarding the legality of the supplement DMAA, or 1,3-dimethylamylamine.

To read the article, click here.

Marc Ullman was quoted in a July 20, 2017 article entitled, “Executive Sold DMAA Supplements, Sentenced to Prison.” The story centers on the president of a dietary supplement company who was sentenced to an 18-month prison term for failing to disclose the presence the amphetamine derivative DMAA on the product labeling for his company’s supplements.

On June 26, Steven Shapiro will speak at the Dietary Supplements conference, a collaboration between the American Conference Institute and the Council for Responsible Nutrition. He will participate on a panel entitled, “FDA Roundup: Rulemaking and Other Activity Impacting the Dietary Supplement Industry,” where he will discuss the new Generally Recognized as Safe (GRAS) Rule and

Marc Ullman was quoted in an article entitled, “How Will Donald Trump Affect Global Ingredient Sourcing?,” which was published in the April 2017 issue of Nutritional Outlook.

Click here to read the article.

Steven Shapiro authored an article for the April 2017 issue of Nutrition Industry Executive.  The article presents a case study in the enforcement of laws prohibiting false and deceptive advertising in connection with the marketing of nutritional supplements.

Click here to read the article.